Axicabtagene Ciloleucel for Follicular Lymphoma: Julio Chavez, MD

Recently, the FDA approved axicabtagene ciloleucel (Yescarta®, Kite Pharma, Inc.) for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, including the combination of an anti-CD20 monoclonal antibody and an alkylating agent. The approval was based on results from ZUMA-5, a phase 2 trial in which axicabtagene ciloleucel demonstrated a high rate of efficacy. In this interview, one of the study investigators, Julio Chavez, MD, of the Moff...

Continue reading

Advising Patients on Follicular Lymphoma Treatment: An Interview With Carla Casulo, MD

Receiving a cancer diagnosis can be devastating, confusing, and overwhelming. It is important for oncologists to be thorough in explaining the treatment process to patients. In this interview with i3 Health, Carla Casulo, MD, Associate Professor at the University of Rochester Medical Center, gives advice on counseling patients diagnosed with follicular lymphoma. What questions do you commonly encounter from patients or caregivers about their treatment, and how do you counsel them? Carla Casulo, ...

Continue reading

Lenalidomide/Rituximab for Follicular Lymphoma and Marginal Zone Lymphoma: John P. Leonard, MD

This week, the FDA approved lenalidomide (Revlimid®, Celgene Corporation) in combination with a rituximab product for relapsed/refractory follicular lymphoma (FL) and relapsed/refractory marginal zone lymphoma (MZL). In this interview with i3 Health, John P. Leonard, MD, lead author of the AUGMENT trial, on which the approval was based, discusses the approval's importance and shares his advice for physicians treating patients with relapsed/refractory FL or MZL. Can you comment on the significanc...

Continue reading

Evolving Treatment and Best Practices in Early Relapsed Follicular Lymphoma: An Interview With Carla Casulo, MD

Accounting for about one third of non-Hodgkin lymphoma cases, follicular lymphoma is a heterogeneous cancer, making it difficult to treat. When a patient relapses or has refractory disease, it becomes an even more difficult challenge to treat. However, continued research has brought significant treatment advances. Carla Casulo, MD, Associate Professor at the University of Rochester Medical Center, has conducted extensive research on follicular lymphoma and treats many patients with this dis...

Continue reading

Lenalidomide Approved: Follicular Lymphoma and Marginal Zone Lymphoma

​The FDA has approved lenalidomide (Revlimid®, Celgene Corporation) in combination with a rituximab product for relapsed/refractory follicular lymphoma (FL) and relapsed/refractory marginal zone lymphoma (MZL). Follicular lymphoma is the most common form of indolent (slow growing) B-cell non-Hodgkin lymphoma (NHL), accounting for around 20% to 30% of all NHL cases. Marginal zone lymphoma, another type of indolent B-cell NHL, comprises approximately 8% of all NHLs. "Current treatment options for ...

Continue reading

Predicting and Managing Early Relapse in Follicular Lymphoma: An Interview With Carla Casulo, MD

Due to its heterogeneity, follicular lymphoma is a difficult cancer to treat. Often, patients experience relapse. Carla Casulo, MD, Associate Professor at the University of Rochester Medical Center, has done extensive research on follicular lymphoma and treats many patients with this disease. In an interview with i3 Health, Dr. Casulo shares insights on predicting and managing relapsed follicular lymphoma. What are some risk factors that could predict early relapse of follicular lymphoma? D...

Continue reading

Follicular Lymphoma: Types of T Cells Affect Outcome

Researchers have identified subtypes of T cells occurring within the follicular lymphoma (FL) microenvironment that have differing impacts on patients' chances of survival. With a median five-year survival of 74% for patients with FL treated with chemoimmunotherapy, this form of treatment has substantially improved outcomes. For a subset of patients who experience early disease progression, however, survival rates remain very low. Part of the reason for the poor outcome among these patients is a...

Continue reading

Duvelisib Approved for Non-Hodgkin Lymphoma Subtypes

The FDA has now granted regular approval to duvelisib (Copiktra®, Verastem, Inc.) as a third-line or later treatment for adults with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). The FDA has also granted duvelisib accelerated approval as a third-line or later treatment for adults with relapsed or refractory follicular lymphoma (FL). Both CLL/SLL and FL are slow-growing types of non-Hodgkin lymphoma characterized by high rates of relapse, with limited...

Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2022 Oncology Data Advisor. All rights reserved.